Vir to present expanded Phase 2 SOLSTICE data on elebsiran-tobevibart combo in hepatitis delta at AASLD 2026

• Vir Biotechnology flagged expanded Phase 2 SOLSTICE results for elebsiran with tobevibart in chronic hepatitis delta for future presentation.
• Data are scheduled for AASLD The Liver Meeting 2026 in Denver, running Nov. 5-9, with an efficacy-focused update through Week 96.
• A separate oral presentation will cover a translational sub-study assessing intrahepatic immune-cell changes seen with the regimen.
• The monthly, two-injection combination targets hepatitis B surface antigen to block viral entry, lower circulating particles, and curb ongoing hepatitis delta replication.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vir Biotechnology Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610051605BIZWIRE_USPR_____20261005_BW191358) on October 05, 2026, and is solely responsible for the information contained therein.